AstraZeneca PLC
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZEG.F | MRK | PFE | NVS | LLY | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 238.22B | 358.41B | 171.16B | 287.24B | 1.14T | 37.04B |
| P/E (TTM) | 26.8 | 117.2 | 39.5 | 22.8 | 42.7 | 44.5 |
| Forward P/E | — | 15.7 | 10.4 | 15.4 | 27.0 | 15.2 |
| Price/book | 5.3 | 8.6 | 2.0 | 6.9 | 33.5 | 2.0 |
| Dividend yield | 1.83% | 2.31% | 5.65% | 3.03% | 0.53% | — |
| 1-year change | +6.84% | +66.04% | +21.28% | +15.93% | +54.27% | +69.35% |
| Today | −0.13% | −1.34% | −1.28% | −3.30% | −2.54% | −1.24% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All ZEG.F news ›AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 Earnings
AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. Click here to read more on AZN. - AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product…
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance. For sponsors and clinical operations teams, the announcement is a statement of intent rather…
AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval
AstraZeneca (AZN) shares drew investor attention on Thursday after the biopharmaceutical company announced the U.S. launch of its lung cancer drug Zegfrovy (Sunvozertinib). The drug is indicated for adults with locally advanced or…
AstraZeneca says FDA approves drug for rare kidney disease in adults
• AstraZeneca said the treatment Ultomiris reduced proteinuria — excess protein in the urine — by 43.4% compared with placebo after 34 weeks in an interim analysis of the late-stage trial • The drugmaker said the FDA granted the approval…
AstraZeneca partners with Oracle for AI-driven clinical trials
pharma.economictimes.indiatimes.com AstraZeneca partners with Oracle for AI-driven clinical trials - Published On Oct 21, 2026 at 07:24 AM IST Find this Comment Offensive? Join the community of 2M+ industry professionals. All about…
AstraZeneca, Oracle Join Forces to Use AI in Clinical Trials, Target Faster Drug Development
Bengaluru: AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve…
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
pharma.economictimes.indiatimes.com AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Published On Oct 21, 2026 at 07:17 AM IST Find this Comment Offensive? Join the community of 2M+ industry professionals. All…
National Grid revamps; AstraZeneca in merger talks
Published on 08/03/2026 at 02:59 am EDT (Alliance News) - National Grid unveiled a streamlined operating model aimed at improving execution, while easyJet extended the deadline for rival bidder Castlelake to make a takeover offer.…
AstraZeneca PLC Through Alexion, AstraZeneca Rare Disease Receives Accelerated Approval In The US For Ultomiris To Reduce Proteinuria In Adults With Primary Immunoglobulin A Nephropathy
Published on 10/22/2026 at 12:41 pm EDT Alexion, AstraZeneca Rare Disease?s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease…
Amgen and AstraZeneca report Phase III Tezspire data for EoE
Amgen and AstraZeneca have reported complete results from the Phase III CROSSING clinical trial of Tezspire (tezepelumab-ekko) for adolescent and adult patients with uncontrolled, symptomatic eosinophilic oesophagitis (EoE). Subcutaneous…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com46
-
tradingview.com15
-
seekingalpha.com7
-
biospace.com6
-
statnews.com6
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.